A detailed history of Assenagon Asset Management S.A. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 257,103 shares of CLSD stock, worth $262,245. This represents 0.0% of its overall portfolio holdings.

Number of Shares
257,103
Previous 283,193 9.21%
Holding current value
$262,245
Previous $368,000 11.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$0.93 - $1.35 $24,263 - $35,221
-26,090 Reduced 9.21%
257,103 $326,000
Q2 2024

Jul 18, 2024

BUY
$1.08 - $1.58 $305,848 - $447,444
283,193 New
283,193 $368,000
Q2 2023

Jul 25, 2023

SELL
$0.97 - $1.48 $77,466 - $118,195
-79,862 Reduced 52.67%
71,776 $80,000
Q1 2023

Apr 18, 2023

SELL
$0.93 - $1.66 $14,827 - $26,467
-15,944 Reduced 9.51%
151,638 $157,000
Q4 2022

Jan 12, 2023

SELL
$1.0 - $1.5 $243,109 - $364,663
-243,109 Reduced 59.2%
167,582 $188,000
Q3 2022

Oct 27, 2022

SELL
$1.08 - $1.83 $373,149 - $632,281
-345,509 Reduced 45.69%
410,691 $464,000
Q2 2022

Jul 27, 2022

SELL
$1.3 - $2.49 $204,865 - $392,396
-157,589 Reduced 17.25%
756,200 $1.11 Million
Q1 2022

Apr 25, 2022

SELL
$1.35 - $2.88 $972,841 - $2.08 Million
-720,623 Reduced 44.09%
913,789 $2.09 Million
Q4 2021

Feb 01, 2022

BUY
$2.72 - $5.72 $4.39 Million - $9.24 Million
1,615,538 Added 8559.6%
1,634,412 $4.5 Million
Q3 2021

Oct 19, 2021

BUY
$4.83 - $7.2 $91,161 - $135,892
18,874 New
18,874 $113,000
Q2 2021

Jul 15, 2021

SELL
$2.32 - $5.38 $281,455 - $652,685
-121,317 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$2.24 - $4.25 $271,750 - $515,597
121,317 New
121,317 $300,000

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $61.4M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.